Opinion on Ibrutinib on 1st Line CLL

Paul M. Barr MD Associate Professor of Medicine at Wilmot Cancer Institute provides his opinion on ibrutinib in 1st line chronic lymphocytic leukemia (CLL). Author: obr Added: 06/25/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts